Search results for "GENE THERAPY"

showing 10 items of 53 documents

Baculoviral display of functional scFv and synthetic IgG-binding domains.

2000

Viral vectors displaying specific ligand binding moities such as scFv fragments or intact antibodies hold promise for the development of targeted gene therapy vectors. In this report we describe baculoviral vectors displaying either functional scFv fragments or the synthetic Z/ZZ IgG binding domain derived from protein A. Display on the baculovirus surface was achieved via fusion of the scFv fragment or Z/ZZ domain to the N-terminus of gp64, the major envelope protein of the Autographa californica nuclear polyhedrosis virus, AcNPV. As examples of scFv fragments we have used a murine scFv specific for the hapten 2-phenyloxazolone and a human scFv specific for carcinoembryonic antigen. In pri…

Genetic enhancementvirusesRecombinant Fusion ProteinsBlotting WesternBiophysicschemical and pharmacologic phenomenaEnzyme-Linked Immunosorbent AssayVectors in gene therapySpodopteraBiochemistryViral vector03 medical and health sciencesMice0302 clinical medicineAntibody SpecificityPeptide LibraryAnimalsHumansMolecular BiologyImmunoglobulin FragmentsCells Cultured030304 developmental biology0303 health sciencesbiologyOxazoloneNuclear Polyhedrosis VirusCell Biologyrespiratory systembiology.organism_classificationMolecular biology3. Good healthCarcinoembryonic AntigenAutographa californicaIgG binding030220 oncology & carcinogenesisImmunoglobulin Gbiology.proteinBinding Sites AntibodyAntibodyHaptenBaculoviridaeHaptensViral Fusion ProteinsBiochemical and biophysical research communications
researchProduct

Facilitating matched pairing and expression of TCR chains introduced into human T cells.

2006

AbstractAdoptive transfer of T lymphocytes is a promising treatment for a variety of malignancies but often not feasible due to difficulties generating T cells that are reactive with the targeted antigen from patients. To facilitate rapid generation of cells for therapy, T cells can be programmed with genes encoding the α and β chains of an antigen-specific T-cell receptor (TCR). However, such exogenous α and β chains can potentially assemble as pairs not only with each other but also with endogenous TCR α and β chains, thereby generating αβTCR pairs of unknown specificity as well as reducing the number of exogenous matched αβTCR pairs at the cell surface. We demonstrate that introducing cy…

GeneticsAdoptive cell transferTranscription GeneticCD3T-LymphocytesImmunologyGenetic transferT-cell receptorReceptors Antigen T-CellCell BiologyHematologyT lymphocyteGene TherapyBiologyBiochemistryCell biologyCell LineAntigenCell cultureProtein Biosynthesisbiology.proteinHumansCysteineReceptorBlood
researchProduct

The Challenge of Using CB-HSCs As Source for Gene Therapy: Lentiviral Vector Transduction, Phenotypic Characterization and Global Gene Expression Pro…

2015

Abstract Introduction: Genetic modification of autologous hematopoietic stem and progenitor cells (HSPC) is a promising clinical intervention to cure inherited monogenic diseases. Successful gene therapy trials have already been conducted using CD34+ cells from bone marrow and from mobilized peripheral blood. In this regard, cord blood (CB) represents an attractive source of HSCs due to its high concentration of high proliferative HSPC and increased susceptibility to be transduced by lentiviral vectors. Unfortunately, the major disadvantage is the limited number of HSC in the CB collection. Consequently, ex-vivo expansion of CB-HSC is desirable to extend clinical applications. Purposes: To …

ImmunologyCD34Cell BiologyHematologyBiologyCD38BiochemistryMolecular biologyViral vectorGene expression profilingHaematopoiesisSettore BIO/18 - GeneticaCB-HSCs Gene Therapy Gene Expression Profile of Ex-Vivo Expanded CB CD34+ Cells.Cell cultureImmunologyProgenitor cellInterleukin 3
researchProduct

Non-viral VEGF(165) gene therapy--magnetofection of acoustically active magnetic lipospheres ('magnetobubbles') increases tissue survival in an overs…

2008

Abstract Adenoviral transduction of the VEGF gene in an oversized skin flap increases flap survival and perfusion. In this study, we investigated the potential of magnetofection of magnetic lipospheres containing VEGF165-cDNA on survival and perfusion of ischemic skin flaps and evaluated the method with respect to the significance of applied magnetic field and ultrasound. We prepared perfluoropropane-filled magnetic lipospheres (‘magnetobubbles’) from Tween60-coated magnetic nanoparticles, Metafectene, soybean-oil and cDNA and studied the effect in an oversized random-pattern-flap model in the rats (n= 46). VEGF-cDNA-magnetobubbles were administered under a magnetic field with simultaneousl…

MalePathologymedicine.medical_specialtyNecrosismagneticAngiogenesisGenetic enhancementDermatologic Surgical ProceduresEnzyme-Linked Immunosorbent AssayTransfectionSurgical FlapsRats Sprague-DawleyMagneticsangiogenesismagnetobubblesmedicineAnimalsUltrasonicsSkinbusiness.industryVascular Endothelial Growth FactorsMusclesUltrasoundGraft SurvivalCell BiologyTransfectionGenetic TherapySkin TransplantationArticlesequipment and suppliesLipidsVEGFgene therapyMicrospheresRatsMicrovesselsModels AnimalMagnetofectionMolecular MedicineMagnetic nanoparticleslipospheresmedicine.symptombusinessPerfusionhuman activitiesmagnetofectionJournal of cellular and molecular medicine
researchProduct

Epigenetic upregulation of endogenous VEGF-A reduces myocardial infarct size in mice.

2014

“Epigenetherapy” alters epigenetic status of the targeted chromatin and modifies expression of the endogenous therapeutic gene. In this study we used lentiviral in vivo delivery of small hairpin RNA (shRNA) into hearts in a murine infarction model. shRNA complementary to the promoter of vascular endothelial growth factor (VEGF-A) was able to upregulate endogenous VEGF-A expression. Histological and multiphoton microscope analysis confirmed the therapeutic effect in the transduced hearts. Magnetic resonance imaging (MRI) showed in vivo that the infarct size was significantly reduced in the treatment group 14 days after the epigenetherapy. Importantly, we show that promoter-targeted shRNA upr…

MaleVascular Endothelial Growth Factor ASmall interfering RNAAnatomy and PhysiologyTranscription GeneticMyocardial InfarctionEndogenyCardiovascularCardiovascular SystemEpigenesis GeneticSmall hairpin RNAMiceMolecular cell biologyNucleic AcidsGene expressionProtein IsoformsRNA Small InterferingCyclic AMP Response Element-Binding ProteinPromoter Regions GeneticRegulation of gene expressionMultidisciplinaryChromosome BiologyQRGenomicsGene TherapyChromatinInterventional CardiologyCell biologyUp-RegulationVascular endothelial growth factor AMedicineEpigeneticsDNA modificationHistone modificationResearch ArticleTranscriptional ActivationDrugs and DevicesScienceDNA transcriptionBiologyDownregulation and upregulationGenomic MedicineGeneticsGene silencingAnimalsGene SilencingBiologyBase SequenceInverted Repeat Sequencesta1182Membrane ProteinsDNA MethylationPhosphoproteinsMolecular biologyMice Inbred C57BLRNAGene expressionPloS one
researchProduct

Human Oxidation-Specific Antibodies Reduce Foam Cell Formation and Atherosclerosis Progression

2011

ObjectivesWe sought to assess the in vivo importance of scavenger receptor (SR)–mediated uptake of oxidized low-density lipoprotein (OxLDL) in atherogenesis and to test the efficacy of human antibody IK17-Fab or IK17 single-chain Fv fragment (IK17-scFv), which lacks immunologic properties of intact antibodies other than the ability to inhibit uptake of OxLDL by macrophages, to inhibit atherosclerosis.BackgroundThe unregulated uptake of OxLDL by macrophage SR contributes to foam cell formation, but the importance of this pathway in vivo is uncertain.MethodsCholesterol-fed low-density lipoprotein receptor knockout (LDLR−/−) mice were treated with intraperitoneal infusion of human IK17-Fab (2.…

MaleoxidationGenetic enhancementGreen Fluorescent Proteins030204 cardiovascular system & hematologymedicine.disease_causeArticleAdenoviridaeMice03 medical and health sciences0302 clinical medicineIn vivoAnimalsHumansantibodiesMedicineScavenger receptorReceptorImmunoglobulin Fragments030304 developmental biologyFoam cellHomeodomain ProteinsMice Knockout0303 health sciencesbiologybusiness.industryMacrophagesscavenger receptorsgene therapyRecombinant Proteins3. Good healthLipoproteins LDLMice Inbred C57BLAdenoviridaeReceptors LDLImmunologyDisease ProgressionCancer researchbiology.proteinlipids (amino acids peptides and proteins)atherosclerosisAntibodyCardiology and Cardiovascular MedicinebusinessFoam CellsLipoproteinJournal of the American College of Cardiology
researchProduct

Granulocyte–Colony Stimulating Factor plus Plerixafor in Patients with β-thalassemia Major Results in the Effective Mobilization of Primitive CD34+ C…

2017

Successful gene therapy for β-thalassemia requires optimal numbers of autologous gene-transduced hematopoietic stem and progenitor cells (HSPCs) with high repopulating capacity. Previous studies suggested superior mobilization in these patients by the combination of granulocyte–colony stimulating factor (G-CSF) plus plerixafor over single agents. We mobilized four adult patients using G-CSF+plerixafor to assess the intra-individual variation of the circulating CD34+ cells number and subtypes preand post-plerixafor administration. The procedure was well-tolerated and the target cell dose of ≥8×10 6 CD34+ cells/kg was achieved in three of them with one apheresis procedure. The addition of ple…

Mobilizationbusiness.industryCD34+ cells expression profilingCd34 cellsPlerixaforGenetic enhancementβ-thalassemia; CD34 cells expression profiling; G-CSF plerixafor mobilization; gene therapygene therapySettore MED/15 - Malattie Del SangueGranulocyte colony-stimulating factorSettore BIO/18 - Geneticagene therapy.β-thalassemiaGene expressionImmunologyCancer researchG-CSF+plerixafor mobilizationMedicineDiseases of the blood and blood-forming organsIn patientβ-thalassemia; CD34+ cells expression profiling; G-CSF+plerixafor mobilization; gene therapyRC633-647.5businessβ thalassemia majormedicine.drugThalassemia Reports
researchProduct

Glial Promoter Selectivity following AAV-Delivery to the Immature Brain

2013

Recombinant adeno-associated virus (AAV) vectors are versatile tools for gene transfer to the central nervous system (CNS) and proof-of-concept studies in adult rodents have shown that the use of cell type-specific promoters is sufficient to target AAV-mediated transgene expression to glia. However, neurological disorders caused by glial pathology usually have an early onset. Therefore, modelling and treatment of these conditions require expanding the concept of targeted glial transgene expression by promoter selectivity for gene delivery to the immature CNS. Here, we have investigated the AAV-mediated green fluorescent protein (GFP) expression driven by the myelin basic protein (MBP) or gl…

MouseCanavan DiseaseGene ExpressionDevelopmental and Pediatric NeurologyPediatricsGreen fluorescent protein0302 clinical medicineGene expressionNeurobiology of Disease and RegenerationTransgenesPromoter Regions GeneticCells Cultured0303 health sciencesMultidisciplinaryGlial fibrillary acidic proteinQStatisticsRAge FactorsBrainGenomicsGene TherapyAnimal ModelsDependovirusOligodendrogliamedicine.anatomical_structureNeurologyOrgan SpecificityMedicineGenetic EngineeringResearch ArticleBiotechnologyScienceTransgeneCentral nervous systemGenetic VectorsGreen Fluorescent ProteinsGene deliveryBiologyBiostatistics03 medical and health sciencesModel OrganismsGenomic MedicineDevelopmental NeuroscienceNeuroglial DevelopmentGlial Fibrillary Acidic ProteinmedicineGeneticsAnimalsBiology030304 developmental biologyClinical GeneticsMyelin Basic ProteinGenetic TherapyMolecular biologyOligodendrocyteMyelin basic proteinMice Inbred C57BLAnimals NewbornAstrocytesbiology.protein030217 neurology & neurosurgeryMathematicsTransgenicsNeurosciencePLoS ONE
researchProduct

Adenoviral RB2/p130 gene transfer inhibits smooth muscle cell proliferation and prevents restenosis after angioplasty.

1999

Abstract —Smooth muscle cell (SMC) proliferation that results in neointima formation is implicated in the pathogenesis of atherosclerotic plaques and accounts for the high rates of restenosis that occur after percutaneous transluminal coronary angioplasty, a widespread treatment for coronary artery disease. Endothelial lesions trigger intense proliferative signals to the SMCs of the subintima, stimulating their reentry into the cell cycle from a resting G 0 state, resulting in neointima formation and vascular occlusion. Cellular proliferation is negatively controlled by growth-regulatory or tumor-suppressor genes, or both, such as the retinoblastoma gene family members ( RB/p105, p107, RB2…

NeointimaTranscriptional Activationmedicine.medical_specialtyPhysiologyadenovirus; cell cycle; gene therapy; p130; prb2; restenosisCellGenetic VectorsCell Cycle ProteinsPulmonary ArteryMuscle Smooth VascularAdenoviridaeCatheterizationPathogenesisRestenosisRecurrencemedicineAnimalsCarotid StenosisAngioplasty Balloon CoronaryGenes RetinoblastomaCells CulturedNeointimal hyperplasiaWound HealingRetinoblastoma-Like Protein p130business.industryCell growthGenetic transferCell CycleProteinsGenetic TherapyCell cyclemedicine.diseasePhosphoproteinsSurgeryE2F Transcription FactorsRatsDNA-Binding Proteinsmedicine.anatomical_structureCancer researchCardiology and Cardiovascular MedicinebusinessCarotid Artery InjuriesCarrier ProteinsTunica IntimaTranscription Factor DP1Cell DivisionRetinoblastoma-Binding Protein 1Transcription FactorsCirculation research
researchProduct

A Clinical Trial With Chimeric Monoclonal Antibody WX-G250 and Low Dose Interleukin-2 Pulsing Scheme for Advanced Renal Cell Carcinoma

2005

WX-G250 is a chimeric monoclonal antibody that binds to carbonic anhydrase IX(G250/MN), which is present on greater than 95% of RCCs of the clear cell subtype. The suggested working mechanism of WX-G250 is by ADCC. Because the number of activated ADCC effector cells can be increased by a low dose interleukin-2 pulsing schedule, a multicenter study was initiated to investigate whether WX-G250 combined with LD-IL-2 could lead to an improved clinical outcome in patients with progressive RCC.A total of 35 patients with progressive clear cell RCC received weekly infusions of WX-G250 for 11 weeks combined with a daily LD-IL-2 regimen. Patients were monitored longitudinally for ADCC capacity. Radi…

OncologyAdultMalemedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentUrologyMonoclonal antibodyTranslational research [ONCOL 3]Renal cell carcinomaInternal medicineCarcinomaMedicineHumansProspective StudiesCarcinoma Renal CellAgedAntibody-dependent cell-mediated cytotoxicitybiologybusiness.industryAntibodies MonoclonalImmunotherapy gene therapy and transplantation [UMCN 1.4]ImmunotherapyMiddle Agedmedicine.diseaseKidney NeoplasmsImmunologybiology.proteinDisease ProgressionInterleukin-2Drug Therapy CombinationFemaleAntibodybusinessKidney cancerProgressive diseaseThe Journal of Urology
researchProduct